22:23 , Mar 23, 2018 |  BC Extra  |  Preclinical News

Paper reveals tissue-specificity of cancer growth genes

A study led by Harvard Medical School and Brigham and Women’s Hospital researchers published in Cell showed genes underlying cancer proliferation perform in a tissue-specific manner, potentially presenting a new development paradigm for targeted cancer...
07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Monocyte chemoattractant protein-1 (MCP-1; CCL2)

Cardiovascular disease INDICATION: Atherosclerosis Mouse studies suggest inhibiting MCP-1 in bone marrow stromal cells could help treat atherosclerosis. In a mouse model of atherosclerosis, MCP-1 knockout in cells expressing nestin (NES) - a marker for...
08:00 , Nov 17, 2014 |  BioCentury  |  Emerging Company Profile

Swift western wind

Zephyrus Biosciences Inc. is developing its scWestern technology to perform Western blots on thousands of cells with single-cell resolution, which will enable researchers to study how protein concentrations vary within heterogeneous cell populations quickly and...
07:00 , Jul 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Adrenergic receptor b3 (ADRB3) Studies in patient samples and mice suggest protecting nestin-positive bone marrow mesenchymal stem cells (MSCs) or their neural regulation could...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

Clavis board of directors update

Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway   Business: Drug delivery, Cancer, Infectious   Transitioned: Martin Nes, a director, to interim chairman; he replaces Anders Wiklund, who resigned  ...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Company News

NsGene, StemCells deal

StemCells acquired from NsGene a patent family, including U.S. Patent Nos. 6,878,543 and 7,303,912 and European patent application 00973148. The patents claim cell cultures of glial fibrillary acidic protein (GFAP) and intermediate filament marker nestin,...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

NanoPass Technologies board of directors update

NanoPass Technologies Ltd. , Nes Ziona, Israel   Business: Drug delivery   Appointed: Hadar Ron, managing partner at Israel HealthCare Ventures; and Marvin Samson, CEO of Samson Medical Technologies LLC  ...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

Prolor preclinical data

In a mouse model of hemophilia, Prolor's Factor VIIa-CTP showed a significantly longer duration of clotting activity vs. an undisclosed commercially available recombinant Factor VIIa product. Prolor plans to start Phase II testing of the...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Company News

Circassia, NanoPass Technologies deal

Circassia received rights to NanoPass' MicronJet microneedle intradermal delivery device for use in allergy vaccine indications. Terms were not disclosed. Circassia is developing allergy vaccines that use its ToleroMune T cell epitope desensitization technology, including...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

hGH-CTP: Phase II data

Top-line data from an open-label, dose-ranging, international Phase II trial in 39 patients showed that a single weekly injection of hGH-CTP containing 30%, 40% or 100% of the equivalent cumulative commercial dose that a patient...